Prerequisites for a dry powder inhaler for children with cystic fibrosis by Lexmond, Anne J et al.
  
 University of Groningen
Prerequisites for a dry powder inhaler for children with cystic fibrosis





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Lexmond, A. J., Hagedoorn, P., Frijlink, H. W., Rottier, B. L., & de Boer, A. H. (2017). Prerequisites for a
dry powder inhaler for children with cystic fibrosis. PLoS ONE, 12(8), [e0183130].
https://doi.org/10.1371/journal.pone.0183130
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
RESEARCH ARTICLE
Prerequisites for a dry powder inhaler for
children with cystic fibrosis
Anne J. Lexmond1*, Paul Hagedoorn1, Henderik W. Frijlink1, Bart L. Rottier2,3, Anne H. de
Boer1
1 Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The
Netherlands, 2 Division of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital,
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 3 Groningen




Correct inhalation technique is essential for effective use of dry powder inhalers (DPIs), as
their effectiveness largely depends on the patient’s inhalation manoeuvre. Children are an
especially challenging target population for DPI development due to the large variability in
understanding and inspiratory capacities. We previously performed a study in which we
determined the prerequisites for a paediatric DPI in a mostly healthy paediatric population,
for which we used an empty test inhaler with variable internal airflow resistance and mouth-
piece. In the current study we investigated what specifications are required for a DPI for
children with cystic fibrosis (CF), for which we expanded on our previous findings. We
recorded flow profiles of 35 children with CF (aged 4.7–14.7 years) at three airflow resis-
tances (0.031–0.045 kPa0.5.min.L-1) from which various inspiratory parameters were com-
puted. Obstructions in the mouth during inhalation were recorded with a sinuscope. All
children were able to perform a correct inhalation manoeuvre, although video analysis
showed that children did not place the inhaler correctly in the mouth in 17% of the cases. No
effect was found of medium to high airflow resistance on total inhaled volume, which implies
that the whole resistance range tested is suitable for children with CF aged 4–14 years. No
effect could be established of either mouthpiece design or airflow resistance on the occur-
rence of obstructions in the mouth cavity. This study confirms our previous conclusion that
the development of DPIs specifically for children is highly desired. Such a paediatric DPI
should function well at 0.5 L inhaled volume and a peak inspiratory flow rate of 20 to 30 L/
min, depending on the internal airflow resistance. This resistance can be increased up to
0.045 kPa0.5.min.L-1 (medium-high) to reduce oropharyngeal deposition. A higher resis-
tance may be less favourable due to its compromising effect on PIF and thereby on the
energy available for powder dispersion.
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Introduction
Correct inhalation technique is essential for effective use of dry powder inhalers (DPIs), as the
therapeutic effect of their use largely depends on the inhalation manoeuvre of the patient. The
inhaled flow rate provides the energy for effective dispersion of the powder formulation and
the delivery of a high fine particle dose, whereas the entire inhalation manoeuvre determines
the lung deposition [1]. Therefore, sufficient inspiratory capacity is needed. In addition,
understanding of how to perform the optimal manoeuvre is essential, which includes deep
exhalation prior to and a sufficiently long breath hold after inhalation of the powder aerosol
[2] to allow for deep penetration in the airways and time for sedimentation respectively. Both
aspects are affected by patient characteristics like age and severity of disease [3–7]. It is, there-
fore, important to study the prerequisites for correct use of DPIs in selected patient
populations.
Children constitute a special and highly heterogeneous target population for inhaled drug
delivery. Lung physiology and cognitive abilities are in development and even within the same
age group a large variability in understanding and inspiratory capacity may exist between indi-
vidual children. Therefore, serving this target population is highly challenging and only devices
that perform largely independent of the patient may be suitable for this group. Young children
may be unable to understand and comply with complex inhalation instructions, whereas the
immature inspiratory capacity may result in the inhalation of only small volumes at low flow
rates. Designers of DPIs for this patient group should take account of these limitations and
variability.
Many children with cystic fibrosis (CF) are treated with inhaled antibiotics, which are fre-
quently administered by nebulisation. To reduce the burden of antibiotic nebulisation, the
first generation capsule-based DPIs with antibiotics (tobramycin and colistimethate) is cur-
rently used, but these DPIs are registered for patients with CF from the age of 6 years onward.
They require inhaled volumes1 L at a moderate to high flow rate (40 L/min) to deliver the
entire dose in the capsule in one inhalation [8]. To ensure complete dose emission, patients
are therefore advised to inhale multiple times from one capsule if necessary [9,10]. One dose
dry powder tobramycin is contained in four capsules that have to be inhaled consecutively,
quadrupling the number of inhalations per dose administration. Young children cannot
achieve such high volumes and high flow rates [7], and thus they require multiple inhalations
to receive the full dose. This makes the administration lengthier and more burdensome, espe-
cially for tobramycin. Additionally and perhaps more importantly, most studies report only
the effects of flow rate and inhaled volume on the emitted dose [8,11], while the dispersion effi-
cacy may be severely compromised when the device is operated at lower values. It has been
shown for the colistimethate capsule DPI that dispersion is already poor when operated at a
flow rate of 65 L/min (4 kPa), resulting in a fine particle fraction of 1–5 μm of 20% of the emit-
ted dose [12]. At this flow rate, an estimated 40 to 50% of this fraction is deposited in (adult)
lungs [13], resulting in an effective lung dose of around 10% of the emitted dose. Larger parti-
cles (>5 μm) are more likely to be deposited in the oropharyngeal region [13]. When the
patient inhales with a lower flow rate, less energy is available for dispersion and a shift towards
larger particles (agglomerates) and hence more oropharyngeal deposition will occur. In chil-
dren the effects of this reduced dispersion efficacy on oropharyngeal deposition can be even
more detrimental due to their smaller anatomical dimensions. Therefore, the development of
DPIs especially for children that are designed to function optimally at low inhaled flow rates
and volumes is warranted. However, it is not known what specifications are required for a DPI
for children with CF.
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adherence to PLOS ONE policies on sharing data
and materials.
Previously we conducted a study in healthy school children to investigate their cognitive
and inspiratory capacities regarding dry powder inhalation [7]. In this study, we determined
requirements for a paediatric DPI using an instrumented test inhaler with variable internal
resistance against airflow and mouthpiece design (Fig 1). Our primary aim was to assess from
what age on children have the cognitive capacity to operate a DPI correctly, how their inspira-
tory capacities were and how various aspects of the inhalation manoeuvre are affected by the
inhaler’s internal airflow resistance and its mouthpiece design. We used the data to determine
the optimal design variables for the development of a paediatric DPI and found that such a
DPI should deliver a sufficiently high fine particle dose within an inhaled volume of 0.5 L, at a
peak inspiratory flow rate of no more than 25–40 L/min (depending on the airflow resistance).
However, the participants in this study were mostly healthy. Chronic pulmonary infection is a
hallmark of lung disease in CF and the resulting inflammatory changes of the airway may
result in reduced lung function. Therefore, we conducted this study in children with CF for
which we used the design variables that appeared to suit healthy children best. Although chil-
dren with CF may have reduced lung function already at a young age [14], they often still dem-
onstrate normal spirometry, which deteriorates significantly as they get older [15]. Therefore,
we expected that the youngest children with CF would have an inspiratory capacity that corre-
sponds fairly well to that of healthy children, but that the older children would lag behind their
peers. We investigated whether the physical limitations for DPI use found in young healthy
children also apply to older children with CF.
Subjects and methods
Study population
Participants were recruited in the outpatient clinic of the Beatrix Children’s Hospital in Gro-
ningen, the Netherlands. Children with CF in the age range 4–14 years of age were eligible for
participation. Written informed consent from the parent(s)/guardian(s)—and if applicable,
from the children themselves—was obtained. The study was conducted according to the prin-
ciples expressed in the Declaration of Helsinki and approved by the Medical Ethics Committee
of the University Medical Center Groningen. Tests were conducted prior to the routine check-
up visit that children with CF undergo every three months in the Netherlands.
Study design
The study was an exploratory non-therapeutic observational study in which the applicability of
dry powder inhalation in children with CF was investigated with an empty instrumented test
inhaler described previously [7]. A computer with data acquisition software (LabView,
National Instruments BV, The Netherlands) recorded the flow profiles (flow rate, derived
from the pressure drop across the inhaler, as function of time) of the children’s inhalations
through the inhaler. The internal airflow resistances and mouthpiece designs of this test
inhaler can be varied and the ones used in this study were those found to be most suitable for
children in the previous study with healthy children. The airflow resistances were 0.031 (R4),
0.039 (R3), and 0.045 kPa0.5.min.L-1 (R2), covering the range of medium to high airflow resis-
tance according to the definition of the ERS/ISAM task force [16]. The two mouthpiece
designs used were oblong and oval (Fig 1). The oblong mouthpiece was most preferred by the
healthy children in the previous study, whereas the oval mouthpiece appeared to have greatest
positive effect on the passageway for an aerosol through the mouth cavity [7].
The study comprised two randomised procedures (see for the randomisation the next para-
graph). Firstly, flow profiles of three inhalations were recorded per child. Secondly, each child
performed three additional inhalations during which the effects of mouthpiece design and
Prerequisites for a dry powder inhaler for children with CF
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Fig 1. The test inhaler used in this study with the oval (top) and oblong mouthpiece design. The test inhaler
is equipped with a differential pressure gauge through the bottom of the handle and connected to a data acquisition
system for recording of the inspiratory flow manoeuvres. The rotatable ring with orifices of different sizes on top is
used to set the airflow resistance. The test inhaler has been described previously in more detail [7].
https://doi.org/10.1371/journal.pone.0183130.g001
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internal airflow resistance on the passageway for the aerosol through the mouth cavity were
investigated using a sinuscope (Olympus WA96200A, Olympus Winter & Ibe GmbH, Ger-
many) that was placed inside the test inhaler. The video recordings from the sinuscope were
used to observe whether or not an obstruction (e.g. from tongue, teeth or cheeks) existed in
the aerosol passageway towards the throat during the inhalation manoeuvre. These videos
were evaluated qualitatively by an experienced investigator, following earlier experience that
the observations of two independent investigators were highly similar [7]. Obstructions were
defined as less than a third (by estimation) of the throat visible, a raised tongue, cheeks curved
inward, or lips and/or teeth in front of the lens. It was also investigated whether condensation
of damp air on the lens of the sinuscope had occurred, which may be an indication of exhala-
tion into the inhaler.
Randomisation for the procedures was performed prior to the measurements by computer
(Excel, Microsoft). One of the two mouthpieces was randomly assigned for the entire first pro-
cedure and the order in which the three airflow resistances were tested was randomised as well
by computer. For the second procedure, two mouthpiece designs and two resistances were
randomly tested per child.
Each child received the following instructions for the inhalation manoeuvre:
• Sit or stand up straight;
• Keep the inhaler in upright position;
• Exhale completely, away from the inhaler;
• Place the inhaler in the mouth and seal teeth and lips around it;
• Inhale as forcefully and as long as possible;
• Take the inhaler from the mouth;
• Hold your breath for ten seconds (or as long as comfortable);
• Exhale.
The children were asked to repeat the instructions or demonstrate the manoeuvre and
when they did so correctly, the measurements commenced.
The inspiratory parameters that were calculated were the maximum pressure drop (dPmax),
the peak inspiratory flow rate (PIF), the mean inspiratory flow rate (MIF), the flow increase
rate (mean acceleration in flow rate from 20% to 80% of PIF; FIR20-80%), the inhaled volume
(Vi), and the total inhalation time (ti).
Data analysis
Routine descriptive statistics of the subject characteristics were performed. Exploratory data
analysis was performed to identify data distribution trends and normality was tested using
Shapiro-Wilk normality test. Because the sample size was limited and the population was quite
skewed towards older children (twelve children12 years of age), variables were generally not
normally distributed. Therefore, for all variables Spearman’s correlation coefficients for non-
normally distributed variables were calculated to study the correlation between the inspiratory
parameters and age. Fixed effects linear mixed models were then used to estimate the effects of
airflow resistance and the children’s characteristics inspiratory parameters after log transfor-
mation to normalise the distributions. The presence of obstructions in the oral cavity and the
effects of mouthpiece design and airflow resistance thereon were evaluated qualitatively.
Prerequisites for a dry powder inhaler for children with CF
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Analyses were performed with SPSS 23 (IBM) and Prism 5.0 (GraphPad Software). All statisti-
cal testing was two-sided, with an α of 0.05.
Results
Study population
35 children were included in the study. All of them were able to comprehend the instructions
and to finish the first procedure. One subject (age 4.9 years) did not perform the second proce-
dure, because she was tired after the first and lost motivation for completing the test. There-
fore, the investigator and child’s mother agreed that it was better to end the measurements.
Descriptive statistics of the study population are shown in Table 1.
Flow profiles and inspiratory parameters
Of a total of 105 recorded flow profiles, six were excluded. One subject was mentally not feel-
ing well and did not put any effort into the inhalations. For that reason these flow profiles were
excluded from analysis. One flow profile of a second subject was excluded because the inhala-
tion was interrupted after 0.5 s. Two flow profiles of two more subjects were excluded due to
technical errors.
Scatter plots of the inspiratory parameters versus age are presented in Fig 2. All parameters
except for FIR20-80% were significantly positively correlated with age. Two children (4.9 and 5.2
years old) inhaled 0.42 L and 0.38 L respectively, all other children reached values of 0.50 L or
higher. Three children (4.9, 7.4, and 7.9 years) did not reach a PIF of 25 L/min through the
high resistance mode of our test inhaler (0.045 kPa0.5.min.L-1). The lowest PIF values on each
resistance were from the same subject (4.9 years), with 21, 27, and 25 L/min at R2, R3, and R4
respectively.
Data processing
The inspiratory parameters from children aged 4–14 years were modelled with the resistance
modes, subject age, height, sex, and lung function parameters FVC (%pred) and FEV1%FVC
as covariates (Table 2). Since height and age are strongly correlated (r = 0.95), a variable was
included for the residual variation in height instead of height to prevent multicollinearity. For
the same reason FEV1%FVC rather than FEV1 (%pred) was included, as the latter correlates
more strongly with FVC (%pred).
Table 1. Descriptive statistics of the study subjects.
Mean Median SD Range
Age (years) 9.9 9.1 3.4 4.7–14.7
Height (cm) 141.7 139.0 19.5 108.3–179.6
Weight (kg) 35.4 30.6 13.0 18.5–63.8
FVC (L) 2.40 2.06 1.09 0.70–6.00
FVC (%pred)* 98 96 18 44–136
FEV1 (L) 1.92 1.73 0.78 0.41–4.26
FEV1 (%pred)* 93 93 20 30–132
FEV1%FVC 81 81 8.3 58–97
Sex Male: 18 (51%) Female: 17 (49%)
FEV1: forced expiratory volume in one second; FVC: forced vital capacity.
*FEV1 and FVC as %predicted were based on Zapletal reference values [17].
https://doi.org/10.1371/journal.pone.0183130.t001
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The resistance modes affected all inspiratory parameters except inhaled volume. At higher
resistance, dPmax and inhalation time increased, whereas FIR20-80%, PIF and MIF decreased. In
the multivariable analysis, age significantly independently affected all parameters except FIR20-
80%. Inhaled volume and inhalation time tended to be lower for girls than boys (p = 0.069 and
p = 0.091 respectively). Another important covariate was FVC, which significantly positively
affected dPmax, PIF, and inhaled volume. FEV1%FVC on the other hand was found to nega-
tively affect inhaled volume only. In Table 3 the estimated means of the inspiratory parameters
are shown per resistance mode to illustrate the extent to which the parameters were affected by
resistance in our study population.
Fig 2. Scatter plots of the inspiratory data versus age. A) maximal pressure drop (dPmax); B) flow increase rate (FIR20-80%);
C) peak inspiratory flow rate (PIF); D) mean inspiratory flow rate (MIF); E) inhaled volume (Vi); F) inhalation time (ti). The dataset
can be found in the Supporting Information (S1 File).
https://doi.org/10.1371/journal.pone.0183130.g002
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Recordings of the mouth cavity during inhalation
In total 102 videos were recorded. In 34% of the video recordings, the passageway was wide
open without visual obstructions. In the 66% of partly obstructed passageways it was mostly
the tongue that prevented a clear view on the back of the mouth cavity. In 17 videos (17%) of
nine children teeth and/or lips were visible (for three children one out of three, for three chil-
dren two out of three, and for three children three out of three recordings). Condensation of
air on the sinuscope lens (an indication of exhalation into the inhaler) occurred in 30% of all
recordings. A rank order was assigned to the three videos per child to investigate whether the
variables airflow resistance and mouthpiece design had an effect on the incidence of obstruc-
tions. Table 4 shows the percentages in which a resistance mode or mouthpiece design had a
positive effect on the passageway relative to the comparator. Because of the qualitative assess-
ment and the small number of cases, no significant effects of any of these variables can be con-
cluded and the results shown are only indicative.
Discussion
This study shows that after good instruction, even young children with CF are able to under-
stand how to inhale correctly through a DPI. Our findings clearly demonstrate that there is no
effect of medium to high airflow resistance on total inhaled volume, which implies that the
whole resistance range tested is suitable for children with CF aged 4–14 years. No effect could
be established of either mouthpiece design or airflow resistance in the tested range on the
occurrence of obstructions in the mouth cavity.
Successful use of a DPI requires that a patient understands how to operate the device and is
capable of handling the inhaler adequately and performing the correct inhalation manoeuvre.
Children constitute a particularly challenging population for DPI use because of their cognitive
Table 3. Estimated means of the inspiratory parameters per resistance mode.
dPmax (kPa) FIR20-80% (L.s-2) PIF (L.min-1) MIF (L.min-1) Vi (L) ti (s)
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
R2 4.04 [3.50–4.65] 1.63 [1.23–2.18] 38.2 [35.1–41.7] 24.4 [22.4–26.6] 0.95 [0.85–1.06] 2.33 [2.11–2.58]
R3 4.05 [3.52–4.67] 2.10 [1.58–2.80] 43.7 [40.1–47.6] 27.8 [25.5–30.2] 1.00 [0.89–1.11] 2.15 [1.95–2.38]
R4 3.50 [3.04–4.04] 2.27 [1.71–3.03] 49.7 [45.5–54.1] 30.1 [27.7–32.8] 1.01 [0.90–1.12] 2.00 [1.80–2.20]
dPmax: maximal pressure drop; FEV1: forced expiratory volume in one second; FIR20-80%: flow increase rate; FVC: forced vital capacity; MIF: mean
inspiratory flow rate; PIF: peak inspiratory flow rate; ti: inhalation time; Vi: inhaled volume. Covariates in the model are evaluated at: Age = 10.0 years; Hresid
= -0.004 cm; FVC = 99.5%pred; FEV1%FVC = 81.8. Values obtained by naïve back transformation of log-transformed estimates.
https://doi.org/10.1371/journal.pone.0183130.t003
Table 4. Percentages of cases in which a DPI design variable affected the aerosol passageway posi-
tively relative to the comparator design variable.
Resistance* Mouthpiece
R2 41% Oval 38%
R3 12% Oblong 30%
R4 26% No difference 32%
No difference 21%
The dataset can be found in the Supporting Information (S2 File).
*Percentages per resistance mode are corrected for the percentage of cases in which each resistance mode
was used.
https://doi.org/10.1371/journal.pone.0183130.t004
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and physical development as they grow up. We investigated whether children with CF are
technically able to operate a DPI using a test inhaler. All children in our study, including the
4-year olds, demonstrated understanding of the inhalation manoeuvre, although one subject
(7.6 years) subsequently failed to do comply with the instructions during the measurements.
This was attributed to poor motivation rather than incomprehension, as she was mentally feel-
ing unwell. Furthermore, correct use of an inhaler also includes correct placement of the
inhaler in the mouth. Our observation of teeth and/or lips in front of the sinuscope lens in a
significant number of cases shows the importance of checking whether the inhaler is actually
placed correctly in the mouth prior to inhalation.
Most studied factors affect the airflow inhaled through the DPI, related to both device
(internal resistance) and patient (age, sex, height, lung function). By modelling the inspiratory
parameters with these covariables, we investigated whether they contribute significantly. In
this study with children with CF, the resistance modes appeared to affect all inspiratory param-
eters except inhaled volume, which implies that the three resistance modes tested can be con-
sidered equally suitable for children with CF in the age range 4–14 years. These findings are in
line with the findings of Tiddens et al., who studied the effect of inhaler resistance in the range
0.019–0.048 kPa0.5.min.L-1 on the inspiratory capacity of CF patients6 years of age, and
found no effect of airflow resistance on inhaled volume [5]. Higher internal airflow resistance
results in a lower inspiratory flow rate, thereby reducing oropharyngeal deposition [13], for
which reason a higher resistance may actually be preferred. However, oropharyngeal deposi-
tion can also be dramatically increased if the inhaler does not disperse well at low flow rates
[18]. Therefore, the inhaler design must ensure effective dispersion at lower inspiratory effort
to benefit from the effect of lower inspiratory flow rate on oropharyngeal deposition. In our
study population the maximum pressure drop over the inhaler was significantly higher at a
medium-high and high resistance compared to the medium resistance, which implies that
more energy is available for dispersion of a drug powder, thus providing additional argument
for a medium-high to high resistance inhaler.
Our results further show that a child’s physical characteristics are important determinants
for its performance. Our dataset is not suitable for building a prediction model with these
characteristics, due to the small sample size and an unequal distribution of children over the
age range as a result of the exploratory study design. However, it can be assumed that besides a
lower age and height, an impaired lung function also affects a child’s inspiratory performance
negatively. This could be especially relevant for children suffering from an exacerbation of
their disease. In particular low FVC (%pred) may be an indicator that a child will not be able
to use a DPI as well as can be expected based on their age.
Key inspiratory parameters for optimal inhaler performance, and thus inhaler design, are
PIF and inhaled volume. A sufficiently high PIF is required for fast and complete entrainment
of the powder formulation from the dose compartment and effective dispersion of that formu-
lation into a suitable aerosol for inhalation. A sufficiently large inhaled volume is needed for
transport of the aerosolised drug particles into the lower airways. We previously concluded
that a paediatric DPI should perform adequately at a PIF of 25–40 L/min (depending on the
airflow resistance) and deliver a sufficient fine particle dose at an inhaled volume of 0.5 L [7].
These values, based on a study population of mostly healthy children of whom the youngest
was 5.3 years old, are slightly lower than those from Tiddens et al. who studied CF patients and
concluded that a DPI that performs optimally at a peak inspiratory flow rate of 30 L/min
with and inhaled volume 1 L would be ideal for most CF patients 6 years of age with dif-
ferent severities of disease [5]. They argue that the need for a larger inhaled volume could
partly be resolved by inhaling the total dose in multiple breaths [5], as is advised for the cap-
sule-based antibiotic DPIs. This is of course a possibility, although there is likely a limit to the
Prerequisites for a dry powder inhaler for children with CF
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number of inhalations beyond which compliance becomes an issue. In the present study we
had even younger children demonstrating a correct inhalation technique and all but two
inhaled 0.5 L or more and all but three reached a PIF of 25 L/min through the high resistance
mode of our test inhaler. This may suggest that although children younger than 5 years can be
technically capable of performing the correct manoeuvre, their smaller inspiratory capacity
may eventually restrict the feasibility of a breath-operated paediatric DPI for this age group, as
accommodating to even lower values for the inspiratory parameters may compromise device
efficacy beyond what is acceptable.
The presence of obstructions in the mouth cavity during inhalation appeared lower than in
healthy children, where we found incidences of obstructions up to 90% [7]. The occurrence of
moisture condensation from exhaled air on the sinuscope lens was comparable to that in
healthy children (39%) [7] and thus, our previous recommendation to equip a paediatric DPI
with suitable means to protect the inhaler’s interior against exhalation through the device is
still relevant. In the present study we limited the design variables to those that appeared most
suitable for children in the first study. We have found no further evidence that any of these
design variables is more suited than the others and it appears that all three resistances and
both mouthpiece designs can be used for a paediatric DPI.
Additional design aspects that should be considered are ease of dose preparation and
inhaler robustness. Although it can be argued that such properties are important for any
inhalation device, particularly for a paediatric DPI it would be valuable if only a few simple
steps are required to prepare the inhaler for use, as well as a robust design that can withstand
rough handling. This could have a positive effect on the child’s ability to use the inhaler
independently.
In conclusion, we found no effect of airflow resistance in the range medium to high on
inhaled volume, which implies that the whole range tested is suitable for children with CF
aged 4–14 years, provided that the effects of airflow resistance on the other inspiratory parame-
ters such as PIF are accounted for in the inhaler design and efficacy. We could not establish an
effect of either mouthpiece design or airflow resistance on the occurrence of obstructions in
the mouth cavity. The present study in CF patients confirms our previous study in healthy sub-
jects and supports our conclusion that the development of DPIs specifically for children is
highly desired. Prerequisites for a paediatric DPI that can be operated by the majority of CF
patients 4 years of age are that it should function well at 0.5 L inhaled volume and a PIF
of 20 to 30 L/min, depending on the internal airflow resistance. Airflow resistance can be
increased up to 0.045 kPa0.5.min.L-1 (medium-high). A higher resistance may be less favour-
able due to its compromising effect on PIF and thereby on the energy available for powder
dispersion.
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